sur Biomind Labs Inc. (CVE:BMND.NE)
Biomind Labs Advances BMND08 with New Nano-Formulation
Biomind Labs Inc., a clinical-stage biopharmaceutical company, has announced a significant advancement for its 5-MEO-DMT candidate, BMND08. The company is now utilizing a proprietary nano-formulation platform, enhancing drug delivery precision and scalability for neuropsychiatric and neurodegenerative disorders. This follows a Phase 2 trial showcasing a 100% response rate in Alzheimer’s-related mood disorders.
The patent application for BMND08 remains in progress, having successfully navigated third-party observations that aimed to challenge its standing. This has reinforced the innovation's strategic importance within CNS therapeutics, highlighting the robustness of Biomind's intellectual property.
CEO Alejandro Antalich emphasized that entering the FDA's commercial pathway marks a transformative phase for the company. In addition, Biomind has granted 6.2 million stock options to certain directors and consultants at an exercise price of $0.35 per share.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biomind Labs Inc.